2019 Partners
Sanofi Digital Medicine, under the Chief Medical Office, improves patient outcomes through the development of innovative technology-driven solutions that when combined with drugs, improve treatment efficacy, safety, adherence and overall experience.
Dthera Sciences is working to create a truly innovative digital therapeutic to meaningfully improve the quality of life and reduce loneliness in those with Alzheimer’s Disease, Dementia, and Senior Isolation.
Cognoa’s digital diagnostics and personalized therapeutics improve the timeliness, scale, and effectiveness of behavioral healthcare. Their first clinically-validated mobile application identified autism on average 13 months earlier than the national average and as early as 18 months – when early intervention has the greatest potential for improved life-long outcomes.
Akili is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. Pioneering the development of digital treatments with direct therapeutic activity and delivered through captivating video game experiences, Akili is advancing a broad pipeline of programs to treat cognitive deficiency.
Canary Health is the leading provider of digital health self-management programs that prevent the progression of chronic diseases including arthritis, depression, diabetes, and heart disease. Our mission is to empower people with the tools, coaching and community support to self-manage their health, enhancing their quality of life, improving health outcomes, and lowering the cost of care.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.
We seek breakthroughs at the intersection of digital technology and neuroscience that are influencing the human experience, such as augmented reality, artificial intelligence, immersive gaming, and closed-loop human-computer systems.
Our portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise.
The Learning Corp designs mobile applications for continuous and customizable therapy for people with speech, language, cognition, memory, and learning disorders.
TALI Health Pty Ltd is based in Melbourne, Australia and is made up of a team of neuroscientists, software engineers, game developers and all-round talented individuals. Our vision is to be a leader in the assessment and treatment of childhood attention difficulties. We aim to assist children in reaching their full potential by providing engaging training software clinically proven to improve core cognitive performance.
TopLine Power® is what Simon-Kucher is all about. We help clients grow revenue through optimization of strategy, pricing, marketing, and sales across industries.
We are a thought leader in these topics at the intersection of digitalization and life sciences, positioning our clients to thrive in the healthcare industry of the future.
EnvoyHealth is the leader in the implementation and delivery of comprehensive commercialization and market access strategies for digital therapeutic brands. Our solutions focus on understanding the needs of your customers and delivering tailored solutions that promote patient engagement, advance payor coverage, and provide you with the data and insights you need to drive your business. In a challenging and complex healthcare environment, you need an experienced team to support your go to market strategy. EnvoyHealth’s leadership team has extensive experience bringing new and innovative products to market. We are here to listen, build, and deliver. Contact us today at Dtx@envoyhealth.is
Match Point, celebrating our 10th Anniversary, provides a unique blend of value-added investment banking, strategic, and operating services to healthcareand technology firms. Founded in 2009, with offices in New York City, San Francisco, and Washington D.C., our team of experienced entrepreneurs, bankers, and operators collaborates to develop and execute creative, innovative, and often out-of-the-box solutions to help our clients achieve superior value.
ZS is the world’s largest firm focused exclusively on helping companies improve overall performance and grow revenue and market share through end-to-end sales and marketing solutions—from customer insights and strategy, to analytics, operations and technology. More than 6,000 ZS professionals in 23 offices worldwide draw on deep industry and domain expertise to deliver impact for clients across multiple industries. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
BrightInsight, a Flex Company, provides the leading global regulated digital health platform for biopharma and medtech. Our medical-grade Internet of Things (IoT) platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices, combination products, apps and Software as a Medical Device, in compliance with security, privacy and regulatory requirements.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.
Be part of the 200+ person audience of senior executives who are driving forward the development of Digital Therapeutics
Learn from the industry-defining speaker faculty, comprised of the pioneers of the industry and the most exciting new-comers
The audience is the who’s who of the industry. From every leading Digital Therapeutic company to Pharma, HCP’s and Investors
“I found this conference eye-opening and had many interesting conversations. I am blown away by the Digital Therapeutics community and its commitment to value-based care”
“The conference was tangible, specific and open. I have never been to a conference of this size with such richness of discussion”
“DTx is the must attend event in our industry”
“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”
“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”
“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”
“DTx is a great event! there is a great mix of digital innovators and large companies which deliver high-quality content. I learn a lot and it’s great to see this community come together and have authentic interactions”
2019 Speakers
Below are the 2019 workshops & agenda.
Details for 2020 will be shared shortly.
Workshops
- Digital Therapeutics 101
- Pharma and Digital Therapeutics
Jeffrey Abraham, Vice President, Market Access & Trade, Akili Interactive
Stacey Curtiss, Senior Director & Leader, Medical Science Liaisons, Akili Interactive
Splitting into smaller working groups, each group will discuss their current views on digital therapeutics as a concept and their views on the different facets of the industry.
- Are we comfortable with the definition of a digital therapeutic?
- Generally speaking, how do payers, pharma and regulatory authorities view digital therapeutics?
- What lessons can we draw on from working with other related industries?
- What are our thoughts on the other similar digital medicine approaches out there?
- What remaining questions do we have about digital therapeutics?
Representative(s) from each group share the main points from their discussion to the whole group. Additional questions form moderators and other group members will be raised during this collaborative discussion.
Leave this workshop with:
- Fundamental questions answered around what a digital therapeutic is being defined as compared to other digital interventions
- A deeper understanding of the current payer and provider perspectives on digital therapeutics and how these are looking to be advanced
- Up-to-date information on the different ways pharma are involved in the industry
- A fundamental understanding of the current regulatory pathways in and around the industry
- A stronger appreciation of the crucial questions facing the industry that will be tackled during the rest of the Summit
James Musick, Vice President & Head, Neurology Patient Technology, UCB
Sasha Said, Vice President, Leerink Transformation Partners
Florian Schubert, Director, Digital Strategy, Sandoz
Chris Wasden, Head of Pharma, Happify
Splitting into smaller working groups, each group will discuss their own thoughts and pharma’s current
thoughts on digital therapeutics and what it is going to take to make DTx-pharma partnerships successful.
- What is our understanding of the expectations from different types of DTx-pharma partnerships?
- How do digital therapeutics fit into the short-term and long-term goals of pharma?
- Are pharma more excited about the therapeutic entity or the data produced by digital therapeutics?
- How should pharma adapt their mindsets to maximize the impact of their work with digital therapeutics?
- How do digital therapeutic companies needs to adapt to maximize the impact of their work with pharma?
Representative(s) from each group share the main points from their discussion to the whole group. Additional questions form moderators and other group members will be raised during this collaborative discussion.
Leave this workshop with:
- Deeper understanding of the current ways pharma are partnering with digital therapeutics companies
- Full clarification on the expectations pharma have when in a working partnership with digital therapeutic companies compared to purely investing in them
- Discussion points around how pharma currently view digital therapeutics in their short-term and long-term strategies
- Understanding around how different departments in pharma will impact their work in this industry and where a change of mindset is needed
- An understanding of why some pharma are still reluctant to partner with digital therapeutic companies
Below is the 2019 agenda. Details for 2020 will be shared shortly.
2019 Agenda
- Day One
- Day Two
Joel Sangerman, Chief Commercial Officer, Click Therapeutics
Anand Iyer, Chief Strategy Officer, WellDoc
Peter Hames, Co-Founder & Chief Executive Officer, Big Health
Anand Iyer, Chief Strategy Officer, WellDoc
Eddie Martucci, Chief Executive Officer, Akili Interactive
Brent Vaughan, Chief Executive Officer, Cognoa
Alex Waldron, Chief Commercial Officer, Pear Therapeutics
David Lee, Partner, Simon Kucher & Partners
These small group discussions provide a unique opportunity to get into the key detail of the challenges and opportunities of crucial questions facing digital therapeutics. Each session has been curated to bring expert moderators together in order for attendees to find questions in a peer-to-peer format.
Attendees will be able to attend 3 roundtables, which are 30 minutes each. Get ready for plenty of takeaways in this 90 minute session!
Ed Cox, Chief Executive Officer, Dthera Sciences
Martin Culjat, Vice President, Scientific & Regulatory Affairs, Dthera Sciences
David Keene, Chief Technology Officer, Dthera Sciences
Giangiacomo Rocco di Torrepadula, Chief Executive Officer & Co-Founder, AMICOMED
Vishal Dubey, Chief Product Officer, AMICOMED
Jeff Gombala, Associate Principal, ZS Associates
Maurice Solomon, Associate Principal, ZS Associates
Debra Reisenthel, Founding CEO, Palo Alto Health Sciences
Matthew Tucker, Executive Director, Marketing Strategy, Highmark Health
Antoun Nabhan, Vice President, Corporate Development, Pear Therapeutics
Kiran Hegde, Head, BD&L, Search and Evaluation, Sandoz
Joe Slavinsky, VP, Business Development, Propeller Health
Sasha Said, Vice President, Leerink Transformation Partners
Matt Cook, Vice President, Commercial Strategy & Business Development, Omada Health
Kal Patel, MD, President, BrightInsight, a Flex Company
Derek Cothran, Senior Vice President, Client Strategy and Development, EnvoyHealth
Moderator: Adam Kaufman, President & Chief Executive Officer, Canary Health
Megan Jones-Bell, Chief Scientific Officer, Headspace
Ed Cox, Chief Executive Officer, Dthera Sciences
David Stevenson, Managing Director, Merck Global Health Innovation Fund
Kim Cornish, Director, Monash Institute of Cognitive & Clinical Neurosciences (MICCN), Monash University | Co-Inventor of Tali Train, Tali Health
Moderator: David Amor, Vice President, Quality & Regulatory Affairs, Pear Therapeutics
Taylor Mahan-Rudolph, Director, Quality & Regulatory, Propeller Health
Austin Speier, Chief Strategy Officer, Click Therapeutics
Chin-Wei Soo, Global Regulatory Head, Combination Products and Devices, Genentech, a Member of the Roche Group
Michael Fahmy, Senior Director, Global Regulatory Affairs, Otsuka
Moderator: Sharief Taraman, Chief Medical Officer, Cognoa | Chief of Neurology, Children’s Hospital of Orange County
Rosemary Ku, Urgent Care Physician, Kaiser Permanente | Founder, Executive Director, Cure Chronic Disease
Stephanie Tilenius, Chief Executive Officer & Founder, Vida Health
Veera Anantha, Founder, CTO & President, The Learning Corp
Mette Dyhrberg, Chief Executive Officer, Mymee
Megan Coder, Executive Director, Digital Therapeutics Alliance
Brad Burkett, Founder & Managing Partner, Match Point Partners LLC
André Heeg, Head of Digital, Sandoz
Moderator: Pierre Leurent, Chief Executive Officer, Voluntis
André Heeg, Head of Digital, Sandoz
Ruchita Sinha, Senior Director, Investment, Sanofi Ventures
Javier Garcia Palacios, Director, Digital Health Ventures, Bayer, #G4A
Matthias Zenker, Partner, GAIA AG
Brian Harris, Co-Founder & CEO, MedRhythms Inc.
Chris Raine, Founder & Chief Executive Officer, Hello Sunday Morning
Abhishek Shah, Chief Executive Officer, Wellthy Therapeutics
Bryce Williams, Vice President, Lifestyle Medicine, Blue Shield of California
David Kim, CEO, DigiTx Partners
Owen McCarthy, Co-Founder & President, MedRhythms Inc.
Shahram Seyedin-Noor, Founder & General Partner, Civilization Ventures
Iana Dimkova, Director, Healthcare Investing, GE Ventures
Mette Dyhrberg, Chief Executive Officer, Mymee
DTx West Venue - The Marriott, San Mateo
We strive to provide inspirational venues that can provide the space needed for an open and widely networked event.
The 2020 summit is back at the Marriott San Mateo, a contemporary hotel just 10 minutes from SFO airport. For 2020 space is bigger and better.
Blending the look and feel of a first class resort with comfort and state of the art conference amenities this venue is the perfect place for learning, networking and relaxing.
Bedrooms can be booked directly with the hotel. We anticipate high demand and recommend that you book early to secure the best possible rate. The Marriott does not offer an exclusive rate for DTx attendees. We have included, in the welcome pack, details of alternative hotels close to the DTx venue.
Partner with us
SPONSORSHIP
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.
DTx West 2019 is the third summit in the series, the first two were sell-outs. We are expecting 200 people at the summit in San Mateo, which is what our attendees and sponsors tell us is the optimum size
We believe that getting the right mix of sponsors is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
With 5 companies confirmed pre-launch, sponsor and supporter spaces are selling fast. Get in touch today to learn more to avoid missing out!
Register for the Event
Pre-launch price expires October 4th
For pricing and booking options please click the button to go to the registration page.